Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer
Stopped early · Phase 1
Conditions studied: Breast Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Giving temperature-sensitive liposomal doxorubicin together with hyperthermia may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of temperature-sensitive liposomal doxorubicin when given together with hyperthermia in treating women with locally recurrent breast cancer.
Key facts
- Study ID
- NCT00346229
- Run by
- Duke University
- People needed
- 29
- Starts
- 2006-04-01
- Expected to finish
- 2011-04-01
- Last updated by the study team
- 2016-03-22
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Duke Cancer Institute — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.